Just one day after the US Treasury Department announced it was looking to clamp down on inversion tax deals, it has been announced that the planned $160bn merger between Pfizer and Dublin-based Allergan has been abandoned.
The Pfizer-Allergan deal has been one of the most intensely debated mergers in US corporate history, as it appeared that the former was looking to avail of what is known as an inversion deal, which…
$160bn Pfizer-Allergan merger now off after US pressure
No comments:
Post a Comment